Is Boothwyn Pharmacy legit?

Boothwyn Pharmacy is a 503A compounding pharmacy based in Kennett Square, PA. It operates under state board of pharmacy licensure. Note: our records show 4 documented regulatory action(s) — see the Regulatory Actions section below.

Where is Boothwyn Pharmacy located?

Boothwyn Pharmacy is headquartered in Kennett Square, PA. The pharmacy is licensed to ship to 0 US states.

What does Boothwyn Pharmacy produce?

Boothwyn Pharmacy produces compounded semaglutide and compounded tirzepatide in addition to other compounded preparations. As a 503A pharmacy, it dispenses compounded medications in response to individual patient prescriptions under state board of pharmacy oversight.

What is the difference between 503A and 503B?

503A pharmacies prepare compounded medications for individual patients in response to specific prescriptions and are regulated primarily by state boards of pharmacy under USP sterile compounding standards. 503B outsourcing facilities register directly with the FDA, follow current Good Manufacturing Practices (cGMP), and can produce compounded medications in larger batches without patient-specific prescriptions. 503B facilities are subject to FDA inspection.

Compounding Pharmacy · Kennett Square, PA · 503A

Boothwyn Pharmacy Review

Boothwyn Pharmacy is a 503A compounding pharmacy in Kennett Square, Pennsylvania that compounded sterile semaglutide and tirzepatide injections. It has an extensive regulatory history including a 2018 FDA warning letter, a July 2025 subpotency recall of compounded semaglutide, a 2025 Pennsylvania $1 million fine and probation over unlicensed compounding of roughly 30,000 weight-loss-drug doses, and a January 2026 FDA warning letter. GLP-1 production was voluntarily suspended in June 2025.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

503A

Location: Kennett Square, PA

Website: boothwyn.com

States licensed: 0

3.5

Weight Loss Rankings Score

out of 10

About this pharmacy

Certifications & Compliance

All sterile compounding pharmacies in the United States are required to follow United States Pharmacopeia General Chapter <797> sterile compounding standards^[4], with finished preparations evaluated against USP <71> sterility testing^[5] and USP <85> bacterial endotoxin testing^[6] as appropriate for the product type.

We have not verified any third-party accreditations for this pharmacy beyond its state pharmacy license.

Drugs Produced

Compounding pharmacies' ability to produce semaglutide or tirzepatide depends on the FDA Drug Shortage List status for each reference product; compounding eligibility can change when a drug moves on or off the shortage list^[7].

Yes

Semaglutide

Compounded semaglutide produced

Yes

Tirzepatide

Compounded tirzepatide produced

States Licensed (0)

Regulatory Actions

2018-07-25

FDA Warning Letter (FEI 560524) issued to Boothwyn Pharmacy LLC following inspection findings related to sterile drug production.

2025-07-09

Class II voluntary recall of compounded semaglutide injection (1,476 vials) for containing less than the specified amount of active ingredient (subpotency).

2025-09

Pennsylvania Department of State fined Boothwyn Pharmacy $1 million and placed it on probation for compounding approximately 30,000 doses of injectable weight-loss drugs in unlicensed, uninspected spaces concealed across four state inspections.

2026-01

FDA Warning Letter citing sterility failures, subpotent semaglutide and tirzepatide formulations, and distribution of sterile products before final sterility results were confirmed. California's Board of Pharmacy also initiated proceedings alleging eleven lots of compounded sterile preparations failed strength and purity requirements.

Weight Loss Rankings Score Breakdown

Accreditation & Compliance6/10

Regulatory Standing5/10

State Coverage0/10

GLP-1 Production10/10

Track Record5/10

Scores are independently researched. See our methodology for details.

High confidence · Last verified 2026-06-04 via manual · How we verify provider data

Frequently Asked Questions

Glossary references

Key terms in this article, linked to their canonical definitions.

Semaglutide · Drugs and brands
Tirzepatide · Drugs and brands
Compounded GLP-1 · Pharmacy and drug forms
503A pharmacy · Pharmacy and drug forms
503B outsourcing facility · Pharmacy and drug forms
PCAB accreditation · Pharmacy and drug forms
Off-label use · Insurance and regulatory
FDA Drug Shortage List · Insurance and regulatory

See Top Semaglutide Providers All Pharmacies

Sources & methodology — as of June 2026

1.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
2.FDA — 503B Outsourcing Facility Registration and Requirements— U.S. Food & Drug Administration.
3.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
4.USP General Chapter <797> — Pharmaceutical Compounding: Sterile Preparations— United States Pharmacopeia.
5.USP General Chapter <71> — Sterility Tests— United States Pharmacopeia.
6.USP General Chapter <85> — Bacterial Endotoxins Test— United States Pharmacopeia.
7.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.